Defeat Duchenne Canadian Conference 2021: Addressing Duchenne muscular dystrophy (DMD) Standards of Care in Canada
The Neuromuscular Disease Network for Canada (NMD4C) in partnership with Jesse’s Journey and Muscular Dystrophy Canada (MDC), is proud to announce the inaugural Defeat Duchenne Canadian Conference, the first national summit solely focused on Duchenne muscular dystrophy (DMD) for health care providers across Canada.
The theme for this year’s virtual event is DMD standards of care (SoC). This three-part conference will bring together subject matter experts from pediatric and adult care for a comprehensive overview of the Canadian adaptation to the international DMD care considerations published in 2018.
What: Defeat Duchenne Canadian Conference: Addressing DMD Standards of Care in Canada
Who should attend: Multidisciplinary health care professionals involved in the care of DMD patients.
Session 1 (of 3): The first session will focus on the following DMD topics:
• Endocrinology management and bone health
• Cardiac management
• Pulmonary management
Friday, June 18, and Saturday, June 19, 2021, from 11 a.m. – 2 p.m. EDT each day. The second and third sessions will take place in September and December – stay tuned for registration later in the year.
Where: Online (Whova + Zoom)
We hope you and your team will join Jesse’s Journey and our partners as we build the future for Duchenne muscular dystrophy in Canada through research and collaboration.
First session of the three-part virtual conference starts June 18 and 19, 2021. Learn more about the sessions and speakers, and register today: www.dmdcanadianconference.com
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.